Intellia Reports Landmark Phase 3 Results for Gene-Editing Therapy Lonvo-z, Initiates BLA Submission
NTLA has more than doubled off its 52-week low of $6.83 on elevated volume (2.2× avg).
Summary
Intellia Therapeutics announced highly positive topline Phase 3 results for its gene-editing therapy, lonvo-z, in hereditary angioedema, marking a significant step towards regulatory approval and potential commercial launch.
Key Events · Product Development and Regulatory · NTLA
-
Positive Phase 3 HAELO Trial Results
The global Phase 3 HAELO clinical trial for lonvo-z in hereditary angioedema (HAE) met its primary and all key secondary endpoints, demonstrating significant efficacy.
-
Significant Efficacy and Safety Profile
A one-time infusion of lonvo-z reduced HAE attacks by 87% versus placebo, with 62% of patients becoming entirely attack-free and therapy-free. Favorable safety and tolerability data were observed, with no serious adverse events.
-
Global First for In Vivo Gene Editing
These results represent a profound milestone as the first Phase 3 data reported for an in vivo gene editing therapy, highlighting the potential of CRISPR technology.
-
Initiation of Rolling BLA Submission
Intellia has initiated a rolling Biologics License Application (BLA) submission to the U.S. FDA for lonvo-z, with plans to complete the filing in the second half of 2026.
Analysis · NTLA · Life Sciences
Intellia Therapeutics announced highly positive topline Phase 3 results for its gene-editing therapy, lonvo-z, in hereditary angioedema (HAE). This marks a global first for in vivo gene editing, demonstrating significant efficacy with an 87% reduction in HAE attacks and 62% of patients becoming attack-free and therapy-free. The favorable safety profile further de-risks the program. The initiation of a rolling Biologics License Application (BLA) submission to the FDA, with an anticipated U.S. launch in the first half of 2027, is a critical step towards commercialization and represents a potential paradigm shift for HAE treatment, offering a one-time curative option. This formal 8-K filing provides the official details and exhibits for the news that was disseminated earlier today.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 41.2% of the 374 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NTLA was trading at $14.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $6.83 to $28.25. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.